Open AccessLumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR
Author(s) -
Steven M. Rowe,
Susanna A. McColley,
Ernst Rietschel,
Xiaolei Li,
Scott C. Bell,
Michael W. Konstan,
Gautham Marigowda,
David Waltz,
Michael Boyle
Publication year - 2017
Publication title -
annals of the american thoracic society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 114
eISSN - 2329-6933
pISSN - 2325-6621
DOI - 10.1513/annalsats.201609-689oc
Subject(s) - ivacaftor , medicine , cystic fibrosis , placebo , regimen , randomized controlled trial , gastroenterology , cystic fibrosis transmembrane conductance regulator , pathology , alternative medicine
In a prior study, lumacaftor/ivacaftor treatment (≤28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom